⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

Molecular classification now guides treatment decisions. Four subtypes — POLE-mutated, MSI-high/dMMR, p53-abnormal, and NSMP — determine prognosis and therapy choices more precisely than stage alone.
Immunotherapy plus chemotherapy is the new first-line standard for advanced disease. Dostarlimab or pembrolizumab combined with carboplatin-paclitaxel has fundamentally changed outcomes, especially for patients with mismatch repair deficient tumors.
Sentinel lymph node mapping has largely replaced full lymphadenectomy. This less invasive approach detects spread accurately while reducing lymphedema risk.
Universal MMR/MSI testing is mandatory for every patient. It determines eligibility for immunotherapy and screens for Lynch syndrome, a hereditary condition that affects your family.
Surgery remains the cornerstone for early-stage disease. A total hysterectomy with removal of both ovaries and fallopian tubes cures the majority of early-stage patients.
FIGO 2023 staging integrates molecular classification for the first time. This means two patients with the same anatomic stage may receive different treatment based on their tumor’s molecular profile.
Fertility-sparing treatment is possible for select young patients. Women with grade 1 endometrioid cancer confined to the endometrium may be treated with progestins to preserve the option of pregnancy.
Obesity is the strongest modifiable risk factor. Excess body weight is linked to roughly half of all endometrial cancer cases. Lifestyle changes matter both for prevention and after treatment.

▼ Collapse

Understanding Endometrial Cancer

Endometrial cancer begins in the lining of the uterus — the endometrium — and is the most common gynecologic cancer in high-income countries. The good news that should anchor every conversation: most endometrial cancers are caught early, when symptoms first appear, and most are curable. Even for patients diagnosed at a more advanced stage, recent advances in immunotherapy have transformed the treatment landscape in ways that were unimaginable just five years ago.

Globally, an estimated 417,367 new cases were diagnosed in 2020, accounting for roughly 2.2% of all cancers. Incidence is rising in nearly every country, driven largely by increasing rates of obesity — endometrial cancer has the strongest obesity-cancer link of any tumor type.

The one symptom that matters most. The single most important thing to know about endometrial cancer is that it usually announces itself early with abnormal vaginal bleeding — bleeding after menopause, or unusually heavy, prolonged, or between-period bleeding before menopause. This is why so many endometrial cancers are caught at an early, curable stage: the body gives a clear warning. Any bleeding after menopause should be evaluated promptly — it is not normal and deserves a doctor’s attention even if it happens only once. Most postmenopausal bleeding turns out to be benign, but because it is also the classic early sign of this cancer, it should always be checked rather than waited out. Acting on this one symptom is the most powerful thing you or a loved one can do, because early-stage endometrial cancer is highly curable with surgery.

Why it develops, and what that means for you. Most endometrial cancers are linked to long-term exposure of the uterine lining to estrogen that is not balanced by progesterone. This is why risk factors include obesity (fat tissue produces estrogen), never having been pregnant, starting periods early or menopause late, polycystic ovary syndrome, diabetes, and taking estrogen-only hormone therapy or tamoxifen. Understanding this is empowering rather than blaming: it explains why managing weight, blood sugar, and overall metabolic health can lower risk, and why these same steps support recovery and reduce the chance of recurrence. A smaller but important group of endometrial cancers — especially in younger women or those with a family history — are linked to an inherited condition called Lynch syndrome, which also raises the risk of colon and other cancers. For this reason, most endometrial tumors are now tested for clues to Lynch syndrome, and if those clues are present you may be referred for genetic counseling. Knowing whether Lynch syndrome runs in your family can protect both you and your relatives through earlier screening.

Not one disease but four. Doctors now understand that endometrial cancer comes in four biological types, identified by testing the tumor’s molecules and genetics. You may hear terms like POLE-mutated (which tends to have an excellent outlook), MMR-deficient/MSI-high (which often responds especially well to immunotherapy and prompts Lynch testing), p53-abnormal (which tends to be more aggressive and is watched more closely), and NSMP (often hormone-sensitive). This is not just academic: this molecular “fingerprint” increasingly guides how much treatment you need — sometimes allowing less treatment for a favorable type, sometimes prompting more for an aggressive one — and it is now part of official cancer staging. It is reasonable to ask your doctor, “What molecular type is my cancer, and how does that affect my treatment?”

Can it be prevented or caught earlier? There is no routine screening test for endometrial cancer in women at average risk — Pap smears screen for cervical, not endometrial, cancer — which makes paying attention to abnormal bleeding all the more important. But several things genuinely lower risk. Maintaining a healthy weight and staying physically active reduce risk substantially, given the strong link between excess body fat, estrogen, and this cancer; managing diabetes and metabolic health helps too. Combined (estrogen-plus-progestin) birth control pills and the progestin-releasing IUD lower long-term risk, and pregnancy and breastfeeding are protective. For women taking hormone therapy after menopause, using estrogen with progesterone (in women who still have a uterus) avoids the increased risk that estrogen alone would carry. For the subset of women with Lynch syndrome, the picture is different and more proactive: because their lifetime risk is high, they are offered specialized surveillance and counseling, and some choose risk-reducing surgery after childbearing — decisions made individually with a genetics team. None of this guarantees prevention, but it means there are real, constructive steps — and that knowing your family history and risk factors is worthwhile.

What the outlook generally is. It helps to hold onto the broad picture, because fear often outruns the facts. The majority of endometrial cancers are diagnosed at an early stage — thanks to that early bleeding warning — and early-stage disease is highly curable, often with surgery alone; five-year survival for cancer confined to the uterus is very high. Outlook is more guarded when the cancer is found at a later stage or is one of the more aggressive types, but even here the picture has improved markedly: immunotherapy and targeted treatments have meaningfully extended survival in advanced and recurrent disease, and the molecular understanding of the cancer now lets treatment be tailored more precisely than ever. Statistics describe groups, not individuals, and they reflect the past more than the rapidly improving present — so they cannot tell you your personal story. What you can do is concrete and genuinely matters: act on abnormal bleeding without delay, get care from a gynecologic oncologist, make sure molecular testing is done, and ask about every appropriate treatment and trial. Those steps, far more than any average, shape what lies ahead.

Key message. Endometrial cancer caught at an early stage has an excellent prognosis. For patients with localized disease, five-year survival rates exceed 90%. The most important early steps are obtaining a tissue diagnosis, ensuring molecular testing is performed, and being seen by a gynecologic oncologist who can coordinate surgery and any additional treatment.

Not all endometrial cancers are the same. They fall into two broad categories based on how they look under the microscope and how they behave:

Endometrioid carcinoma (Type I): This is the most common type, accounting for roughly 80% of cases. It is typically driven by estrogen exposure, tends to be lower grade, and generally carries a favorable prognosis when caught early. Most endometrioid tumors are grade 1 or 2 (well to moderately differentiated).
Non-endometrioid carcinomas (Type II): These include serous carcinoma, clear cell carcinoma, and carcinosarcoma (also called malignant mixed Müllerian tumor). They account for roughly 20% of cases but a disproportionate share of endometrial cancer deaths. They tend to be more aggressive, often present at a higher stage, and require more intensive treatment.

The distinction between these types matters because it influences the surgical approach, the need for adjuvant therapy, and prognosis. However, molecular classification (discussed in detail in the Diagnosis section) is increasingly supplementing and, in some cases, overriding the traditional histologic classification.

The hallmark symptom of endometrial cancer is abnormal vaginal bleeding. This includes:

Postmenopausal bleeding: Any vaginal bleeding after menopause warrants prompt evaluation. Roughly 10% of women with postmenopausal bleeding will have endometrial cancer.
Premenopausal irregular bleeding: Unusually heavy periods, bleeding between periods, or a significant change in menstrual patterns in women over 40.
Other symptoms: Watery or blood-tinged vaginal discharge, pelvic pain or pressure, and unexplained weight loss (more common in advanced disease).

Because symptoms tend to appear early, roughly 70% of endometrial cancers are diagnosed at stage I, when the disease is still confined to the uterus. This is a significant advantage compared to many other cancers.

The central risk factor for endometrioid (Type I) endometrial cancer is prolonged estrogen exposure without adequate progesterone balance. Specific factors include:

Obesity: The strongest modifiable risk factor. Excess adipose tissue converts androgens to estrogen. Women with a BMI over 40 have a roughly 7-fold increased risk compared to those at a healthy weight. Obesity is linked to approximately 50% of endometrial cancer cases.
Diabetes and metabolic syndrome: Independently associated with increased risk, though this is partly mediated through obesity.
Tamoxifen use: Tamoxifen, used to treat breast cancer, has estrogenic effects on the endometrium and increases endometrial cancer risk roughly 2–7 fold.
Estrogen-only hormone replacement therapy (without progesterone) in women with a uterus.
Early menarche and late menopause: More years of menstrual cycling means more cumulative estrogen exposure.
Nulliparity: Never having been pregnant is a risk factor; pregnancy provides a progesterone-dominant hormonal environment.
Lynch syndrome: Women with Lynch syndrome have a 40–60% lifetime risk of endometrial cancer, making it a high-risk hereditary condition for this disease.
Polycystic ovary syndrome (PCOS): Chronic anovulation leads to unopposed estrogen.

An essential caveat: having risk factors does not mean someone caused their cancer, and lacking all risk factors does not guarantee protection. Self-blame is both scientifically inaccurate and emotionally destructive. Direct that energy toward the treatment plan instead.

One of the most important advances in endometrial cancer is the recognition that molecular subtypes predict outcomes far more precisely than stage or grade alone:

POLE-mutated (POLEmut): Excellent prognosis regardless of grade or histology. These tumors have an extraordinarily high number of mutations, which paradoxically makes them highly visible to the immune system. Many patients may safely receive less intensive adjuvant therapy.
MSI-high / dMMR: Good prognosis overall, and importantly, these tumors respond well to immunotherapy. This subtype also flags the need for Lynch syndrome screening.
No specific molecular profile (NSMP): The most common subtype. Intermediate prognosis. Treatment is guided by conventional clinical and pathologic factors.
p53-abnormal (p53abn): The most aggressive subtype, associated with serous, clear cell, and high-grade endometrioid histology. These patients need the most intensive treatment, but even here, outcomes have improved with modern chemoradiation approaches.

The bottom line: two patients with the same stage endometrial cancer may have very different outlooks depending on their molecular subtype. This is why molecular testing is essential for every patient.

For patients diagnosed with advanced or recurrent disease, it is important to know that the treatment landscape has changed fundamentally in the past three years. The addition of immunotherapy to standard chemotherapy has extended survival significantly, and for patients whose tumors are mismatch repair deficient, the benefit has been dramatic. Clinical trials are testing new combinations across all molecular subtypes. This is a disease where real, evidence-based progress is happening now.

What type of endometrial cancer do I have — endometrioid, serous, clear cell, or another type?
What is my molecular subtype (POLE, MSI-high, NSMP, or p53-abnormal)?
Has my tumor been tested for mismatch repair deficiency and should I be evaluated for Lynch syndrome?
What stage is my cancer, and what does that mean for my treatment plan?
Should I be referred to a gynecologic oncologist?
Are there any clinical trials I should consider?

Evaluating Treatment Claims

After an endometrial cancer diagnosis, families will inevitably encounter treatment claims from well-meaning friends, social media, and online forums. A practical filter helps separate genuine options from noise.

A simple way to weigh what you hear. Real, proven cancer treatments share a few features: they are supported by clinical trials published in reputable medical journals, they are recommended in guidelines from organizations like the NCCN or major cancer societies, they are offered by board-certified specialists (for this cancer, a gynecologic oncologist), and their benefits and risks are described honestly rather than as miracle cures. Be cautious of anything that claims to cure cancer “naturally,” promises results that sound too good to be true, requires large out-of-pocket payments for unproven therapies, discourages you from standard treatment, or relies on testimonials instead of evidence. Supplements and alternative remedies deserve special care: some can actually interfere with chemotherapy, immunotherapy, or surgery, so always tell your oncology team about anything you are taking or considering. The most reliable move when you encounter a claim is to bring it directly to your care team and ask, “Is there good evidence for this, and is it safe alongside my treatment?” Complementary approaches that help you cope — good nutrition, gentle exercise, mind-body practices, acupuncture for symptom relief — can absolutely have a place alongside proven treatment; the danger is only when something unproven replaces it or interacts harmfully with it.

When evaluating any treatment claim, ask these questions:

Where is the evidence from — a peer-reviewed medical journal and established guidelines, or an individual testimonial or social media post?
Has it been tested in endometrial cancer specifically, in a randomized clinical trial?
Could it interfere with your standard treatment (chemotherapy, immunotherapy, radiation)?
Does anyone without a financial interest in the product recommend it?
Are the doctors at major gynecologic oncology centers using it?

Be especially cautious of anyone who sells the product they recommend, and of anyone who suggests that standard care (surgery, chemotherapy, immunotherapy) is harmful or unnecessary and should be replaced by a natural or alternative protocol. This advice has cost lives. The safest approach: build on standard evidence-based care, never replace it.

Some patients want to add complementary therapies alongside standard treatment. Some of these — yoga, acupuncture for nausea, mindfulness meditation, guided imagery — have evidence supporting their use for symptom management and quality of life. However:

Always disclose every supplement to your oncologist before taking it. Some supplements can interfere with chemotherapy metabolism, reduce immunotherapy effectiveness, or increase bleeding risk during surgery.
Herbal and “natural” does not mean safe. Many supplements have real pharmacological activity and potential interactions with cancer treatments.
Antioxidant supplements (high-dose vitamins C, E, beta-carotene) are generally not recommended during active chemotherapy or radiation, as they may theoretically protect cancer cells from the intended damage.
Complementary means “in addition to,” not “instead of.” Any provider who tells you to stop standard treatment in favor of their protocol is putting your life at risk.

Action Checklist at Diagnosis

Use this checklist to ensure nothing critical is missed in the first weeks after diagnosis.

The handful of things worth getting right early. A new diagnosis is overwhelming, so focus on a few high-value steps. See a gynecologic oncologist — a surgeon who specializes in women’s cancers; care by a gynecologic oncologist is associated with better outcomes, and most endometrial cancer surgery should be done by one rather than a general gynecologist. Confirm that molecular testing (MMR/MSI, p53, and where relevant POLE and HER2) is being done on your tumor, since it now guides both how much treatment you need and which advanced therapies you qualify for. Ask whether your surgery will be minimally invasive with sentinel lymph node mapping, the modern standard for most patients. If MMR testing suggests Lynch syndrome, ask about genetic counseling — it protects you and your relatives. Bring a companion to appointments to take notes and help you remember and decide, and keep your records, pathology, and contacts in one place. And because most endometrial cancers are caught early and cured, it is reasonable to let this checklist — rather than fear — guide your first weeks.

☐ Diagnosis confirmed on endometrial biopsy or D&C pathology report
☐ Histologic type and grade identified (endometrioid grade 1/2/3, serous, clear cell, carcinosarcoma, or other)
☐ MMR/MSI testing ordered on tumor tissue (mandatory for all patients)
☐ Molecular classification requested (POLE, MMR, p53, NSMP) — confirm with pathologist
☐ Imaging completed: MRI pelvis (myometrial invasion) + CT chest/abdomen/pelvis (distant spread)
☐ CA-125 blood test drawn (baseline, especially for serous or advanced disease)
☐ Gynecologic oncologist identified and consultation scheduled
☐ Records folder started: all pathology reports, imaging, labs, and molecular testing in one place
☐ Second opinion considered, especially for high-grade, unusual histology, or advanced disease
☐ Genetic counseling discussed if dMMR tumor or strong family cancer history (Lynch syndrome screening)
☐ Financial counselor contacted at the treating center
☐ Fertility preservation discussed if premenopausal and childbearing is desired

Diagnosis & Staging

A timely and thorough diagnostic workup is the foundation of the entire treatment plan. The goal is to confirm the diagnosis, determine how far the disease has spread, and obtain the molecular information needed to personalize treatment.

How the diagnosis is usually made. When abnormal bleeding prompts an evaluation, the first steps are typically a pelvic exam and a transvaginal ultrasound to look at the thickness of the uterine lining. The key test is a biopsy of the endometrium — often a quick in-office procedure (endometrial biopsy) and, if that is inconclusive or bleeding continues, a hysteroscopy with dilation and curettage (D&C) under light anesthesia, which lets the doctor look inside the uterus and obtain a fuller sample. A biopsy showing cancer is what confirms the diagnosis; it also provides the tissue used for the molecular testing that now guides treatment. If you have postmenopausal bleeding and an initial test is reassuring but bleeding persists, it is appropriate to push for further evaluation rather than assume all is well.

What staging means — and the modern twist. “Staging” describes how far the cancer has spread, from stage I (confined to the uterus) through stage IV (spread to distant organs). For most women, the stage is determined at the time of surgery, when the uterus and lymph nodes are examined under the microscope; imaging (CT, MRI, or sometimes PET) may be used to look for spread beforehand, especially for higher-risk types. The important modern change is that staging now also incorporates the tumor’s molecular type — the same POLE / MMR-deficient / p53-abnormal / NSMP fingerprint described earlier — because biology predicts behavior better than anatomy alone. This is why your team will order molecular tests on the biopsy or surgical specimen, and why the final treatment plan often comes together a week or two after surgery once all the pathology and molecular results are back. That short wait is normal and ensures the plan is built on complete information.

What other tests you might have. Depending on your situation, the workup may include blood tests and, for higher-risk or more advanced disease, imaging such as a CT scan, pelvic MRI (which shows how deeply the tumor invades the uterine wall), or sometimes a PET scan to look for spread. A blood marker called CA-125 is sometimes checked, especially for serous or more advanced cancers, but it is not a reliable screening or diagnosis tool on its own and a normal value does not rule cancer out — it is most useful for tracking disease that is already known. You may also have testing for inherited risk (genetic counseling for Lynch syndrome) if your tumor’s features suggest it. Not everyone needs every test; your team chooses based on the tumor type and stage. It is always reasonable to ask why a particular test is being done and what the result will change — understanding the “why” makes the process less overwhelming and helps you be an active partner in your care.

After abnormal bleeding prompts evaluation, the diagnostic process typically involves:

Endometrial biopsy: Usually the first step — an office-based procedure where a thin catheter is used to sample the uterine lining. This confirms the diagnosis and provides tissue for histologic and molecular testing.
Transvaginal ultrasound: Measures endometrial thickness. A thickened endometrium in a postmenopausal woman raises suspicion and may prompt biopsy.
Hysteroscopy with dilation and curettage (D&C): Performed if the office biopsy is inconclusive or insufficient. Provides a more complete tissue sample.
MRI of the pelvis: The best imaging study for assessing how deeply the tumor invades the uterine wall (myometrial invasion) and whether the cervix is involved. This helps plan the surgical approach.
CT of the chest, abdomen, and pelvis: Screens for distant metastases, particularly to the lungs, liver, and lymph nodes.
CA-125 blood test: Not diagnostic but useful as a baseline, especially in serous carcinoma or advanced disease.

The FIGO (International Federation of Gynecology and Obstetrics) staging system was updated in 2023, and the changes are significant. For the first time, molecular classification has been integrated directly into the staging system. This means:

Staging now includes an “m” notation (e.g., Stage IAmPOLEmut) that captures the molecular subtype alongside the anatomic stage.
Patients with POLE-mutated tumors may be downstaged to a more favorable risk category, reflecting their excellent prognosis.
Patients with p53-abnormal tumors may be upstaged, reflecting their more aggressive biology.
Lymphovascular space invasion (LVSI) has been incorporated more explicitly into staging decisions.

The practical impact: ask whether your staging uses the 2023 FIGO system, and whether molecular classification has been factored in. This affects adjuvant treatment recommendations.

Molecular classification divides endometrial cancers into four groups based on their genetic features. Think of it as a second layer of diagnosis that looks beyond what the tumor looks like under the microscope to what is actually driving its behavior:

POLE-mutated (POLEmut): These tumors have a defect in the POLE gene, which is responsible for proofreading DNA during cell division. As a result, they accumulate an extraordinarily high number of mutations — paradoxically, this makes them highly visible to the immune system, which attacks them effectively. Prognosis is excellent, and patients may safely receive less intensive adjuvant treatment. This subtype accounts for roughly 5–10% of endometrial cancers.
Mismatch repair deficient / MSI-high (dMMR/MSI-H): These tumors have lost the ability to repair certain types of DNA errors. They also tend to be immunogenic and respond well to immunotherapy with checkpoint inhibitors. This subtype accounts for roughly 25–30% of endometrial cancers. Critically, dMMR status also triggers Lynch syndrome screening — if the deficiency is inherited, it has implications for the patient’s family.
No specific molecular profile (NSMP): The most common subtype, accounting for roughly 40–50% of cases. These tumors lack the defining features of the other three groups. Prognosis is intermediate, and treatment decisions are made based on conventional risk factors such as stage, grade, lymphovascular invasion, and histologic type.
p53-abnormal (p53abn): These tumors carry mutations in the TP53 tumor suppressor gene, which is a key guardian against cancer. This subtype is associated with serous carcinoma, clear cell carcinoma, and high-grade endometrioid tumors. It is the most aggressive subtype, accounting for roughly 10–15% of cases, and typically requires the most intensive adjuvant treatment — but outcomes have improved substantially with modern chemoradiation.

A simple way to remember: POLE-mutated is the best actor, p53-abnormal is the most challenging, and dMMR and NSMP fall in between. The molecular subtype should be part of every treatment discussion.

All endometrial cancers should be tested for mismatch repair (MMR) deficiency — this is now considered standard of care. The testing serves two critical purposes:

Treatment decisions: dMMR/MSI-high tumors are eligible for immunotherapy, which can be highly effective.
Lynch syndrome identification: If the MMR deficiency is inherited (germline), the patient has Lynch syndrome. Women with Lynch syndrome have a 40–60% lifetime risk of endometrial cancer and a 10–20% lifetime risk of ovarian cancer, among other cancer risks.

When a tumor is found to be dMMR, additional testing (including germline genetic testing via blood or saliva) determines whether the cause is inherited or a tumor-specific (somatic) event. If Lynch syndrome is confirmed, first-degree relatives (parents, siblings, children) each have a 50% chance of carrying the same mutation and should be offered genetic counseling and testing.

This cascade testing can save lives by enabling enhanced cancer surveillance in family members before cancer develops.

Endometrioid carcinoma: The most common type (~80%). Graded 1 (well differentiated) through 3 (poorly differentiated). Grade 1–2 are generally lower risk; grade 3 behaves more aggressively and is often grouped with high-risk disease.
Serous carcinoma: Aggressive; tends to spread beyond the uterus even when the primary tumor appears small. Often p53-abnormal on molecular testing. Requires comprehensive staging surgery and adjuvant therapy.
Clear cell carcinoma: Another aggressive type, less common than serous. Prognosis depends heavily on stage and molecular subtype.
Carcinosarcoma (malignant mixed Müllerian tumor): Contains both carcinoma and sarcoma elements. Treated with aggressive surgery and chemotherapy. Now classified as a metaplastic carcinoma rather than a true sarcoma.
Other rare types: Undifferentiated and dedifferentiated carcinoma, mucinous carcinoma, squamous differentiation. These require specialized pathology review.

What histologic type is my endometrial cancer and what grade is it?
Has my tumor been tested for all four molecular subtypes (POLE, MMR/MSI, p53, NSMP)?
What is my FIGO 2023 stage, including molecular classification?
Should I be tested for Lynch syndrome, and if so, what does that mean for my family?
Do I need an MRI before surgery to assess myometrial invasion?
Is there any sign of spread beyond the uterus on imaging?
Should I get a second opinion on my pathology at a specialized center?

Surgery & Adjuvant Therapy

Surgery is the cornerstone of treatment for endometrial cancer. For most patients with disease confined to the uterus or pelvis, a well-performed operation is the single most important step toward cure. The extent of surgery and the need for additional (adjuvant) therapy depend on the stage, histologic type, and molecular subtype.

What the operation involves — and why it’s usually minimally invasive. The standard surgery removes the uterus and cervix (hysterectomy) along with both fallopian tubes and ovaries, and samples key lymph nodes to check whether the cancer has spread. For the great majority of patients this is done minimally invasively — through several small incisions using laparoscopic or robotic techniques — which large studies have shown gives the same cancer outcomes as open surgery but with much less pain, fewer complications, shorter hospital stays (often home the same or next day), and a faster return to normal life. This matters especially because many women with endometrial cancer also have obesity, diabetes, or heart conditions, and the gentler approach is safer for them. To check the lymph nodes, surgeons now usually use sentinel lymph node mapping: a dye highlights the first node(s) the cancer would drain to, so only those are removed and tested, rather than stripping out many nodes. This accurate, targeted approach sharply lowers the risk of leg swelling (lymphedema) that came with the older, more extensive node removal. Ask whether your surgery will be minimally invasive and whether sentinel node mapping will be used.

Preparing for surgery, especially if you have other health conditions. Because endometrial cancer often occurs alongside obesity, diabetes, high blood pressure, or heart and lung conditions, a little preparation makes surgery safer and recovery smoother. Your team may optimize your blood sugar and blood pressure beforehand, review your medications (including blood thinners and diabetes drugs), and sometimes involve other specialists. Simple steps help: moving as much as you comfortably can in the weeks before surgery, not smoking, following any instructions about eating and medications, and arranging help at home for the first week or two. After a minimally invasive operation, many women go home the same day or the next and resume light activity within a couple of weeks, though it is normal to feel tired and to need several weeks before returning to full activity. Ask your surgical team what to expect for your situation, what activity limits apply, and what warning signs (fever, heavy bleeding, severe pain, leg swelling, or shortness of breath) should prompt a call — knowing the plan in advance reduces anxiety and helps you recover with confidence.

Will I need treatment after surgery? For many women with early-stage, favorable-type cancer, surgery alone is curative and no further treatment is needed — an outcome the molecular testing now helps confirm. When additional (adjuvant) treatment is recommended, it is matched to your individual risk: vaginal brachytherapy (a short course of internal radiation to the top of the vagina, where recurrences most often occur) is common for intermediate-risk disease and is very well tolerated; pelvic external-beam radiation or chemotherapy (or both) are used for higher-risk or more advanced disease. A major recent advance is that the cancer’s molecular type now helps decide this: a favorable POLE-type cancer may safely need less treatment, while an aggressive p53-type may warrant more. This is a good thing to discuss explicitly — ask, “Given my stage and molecular type, what adjuvant treatment do I actually need, and what are the trade-offs?”

The standard operation for endometrial cancer includes:

Total hysterectomy: Removal of the uterus and cervix. This is most often performed using a minimally invasive approach (laparoscopic or robotic-assisted), which is associated with faster recovery, less pain, and fewer complications compared to open surgery.
Bilateral salpingo-oophorectomy (BSO): Removal of both ovaries and both fallopian tubes. This eliminates the source of estrogen (which can fuel endometrioid tumors) and allows the ovaries and tubes to be examined for any microscopic spread.
Sentinel lymph node (SLN) mapping: The modern standard for lymph node assessment. A fluorescent dye (indocyanine green, or ICG) is injected into the cervix at the time of surgery. The dye travels to the first lymph nodes that drain the uterus (the sentinel nodes), which are then removed and examined. If the sentinel nodes are cancer-free, the remaining lymph nodes are very likely cancer-free as well.

In experienced hands, SLN mapping achieves a detection rate of roughly 86% with a negative predictive value of 99.6%, as demonstrated in the FIRES trial. This means that when the sentinel node is negative, there is a greater than 99% chance that the remaining nodes are also negative.

Full pelvic and para-aortic lymphadenectomy (removing a large number of lymph nodes from both regions) may still be recommended in certain situations:

Serous or clear cell carcinoma, where the risk of lymph node involvement is higher even with early-appearing disease
Bulky or suspicious lymph nodes seen on imaging or at the time of surgery
Failed sentinel lymph node mapping (no sentinel node is identified on one or both sides)
Carcinosarcoma

The advantage of avoiding full lymphadenectomy when sentinel mapping is adequate is a meaningful reduction in the risk of lymphedema — chronic swelling of the legs that can significantly affect quality of life.

After surgery, the decision about whether additional treatment is needed is one of the most important conversations in the cancer journey. This decision is now driven by a combination of pathologic findings and molecular classification:

Low risk (stage IA, grade 1–2, endometrioid, NSMP or POLEmut, no LVSI): Observation alone. No adjuvant therapy needed. These patients have an excellent prognosis with surgery alone.
Intermediate risk: Vaginal brachytherapy (VBT) — a focused form of radiation delivered internally to the vaginal cuff. It reduces the risk of local recurrence with minimal side effects.
High-intermediate risk: VBT or external beam radiation therapy (EBRT), depending on the specific risk factors present.
High risk: EBRT with or without concurrent chemotherapy. This category includes patients with deep myometrial invasion, high-grade disease, lymph node involvement, or unfavorable molecular features.
p53-abnormal: Chemoradiation is typically recommended. The PORTEC-3 trial demonstrated that adding chemotherapy to radiation significantly improved outcomes for these patients, with a 10-year overall survival of 52.7% compared to 36.6% with radiation alone.
POLE-mutated: Even when other features suggest high risk, POLE-mutated tumors have such excellent outcomes that clinicians are actively investigating whether adjuvant therapy can be safely omitted or reduced. The PORTEC-4a trial has shown that molecular profile-based treatment allocation is feasible and safe.

The chemotherapy backbone, when used, is carboplatin plus paclitaxel — typically given every 3 weeks for 4–6 cycles.

For young women who wish to preserve their fertility, conservative management may be an option under very specific conditions:

Grade 1 endometrioid carcinoma confirmed by expert pathology review
Disease confined to the endometrium (no myometrial invasion on MRI)
No suspicious lymph nodes or distant disease on imaging
No contraindications to progestin therapy
The patient understands and accepts the need for close surveillance

Treatment involves high-dose progestins (such as medroxyprogesterone acetate or megestrol acetate), often with a levonorgestrel intrauterine device (Mirena IUD). Endometrial biopsies are repeated every 3–6 months to assess response. If a complete response is achieved, the patient can attempt pregnancy, but a hysterectomy is ultimately recommended once childbearing is complete.

This approach requires extremely careful patient selection and monitoring by a gynecologic oncologist experienced in fertility-sparing management. The recurrence rate after initial response is roughly 30–40%, which is why definitive surgery after childbearing is strongly recommended.

For caregivers. The emotional weight of a cancer diagnosis that also threatens the ability to have children can be enormous. If the patient is considering fertility-sparing treatment, connecting with a reproductive endocrinologist and a counselor who specializes in oncofertility can provide both practical guidance and emotional support.

Vaginal brachytherapy (VBT): A cylinder is placed in the vagina and delivers radiation directly to the vaginal cuff (the top of the vagina after hysterectomy). Typically 3–5 sessions over 1–2 weeks. Side effects are generally mild and localized.
External beam radiation therapy (EBRT): Radiation is delivered from outside the body, targeting the pelvis and potentially the para-aortic region. Typically 25–28 daily treatments over 5–6 weeks. Side effects include fatigue, bladder irritation, bowel changes, and vaginal dryness.
Combined approach: Some patients receive both EBRT and a brachytherapy boost. This is typically reserved for higher-risk disease.

Recovery from a minimally invasive hysterectomy typically takes 2–4 weeks for basic activities and 4–6 weeks for full recovery. Open surgery may take longer. Practical ways to help:

Prepare meals and manage household tasks during the first 2–3 weeks
Drive the patient to follow-up appointments (she will not be able to drive for 1–2 weeks)
Help manage medications and track side effects
Be prepared for the emotional impact — even when the surgery is curative, the loss of the uterus and ovaries carries emotional weight, particularly for women who have not completed their families
Encourage gentle walking as soon as the surgeon approves, as it aids recovery and prevents blood clots
Watch for warning signs that require medical attention: fever, heavy bleeding, increasing pain, redness or drainage from incision sites, or inability to eat or drink

Will my surgery be performed by a gynecologic oncologist using a minimally invasive approach?
Will sentinel lymph node mapping be used, or do I need a full lymphadenectomy? Why?
Based on my pathology and molecular subtype, do I need adjuvant therapy after surgery?
If radiation is recommended, will it be vaginal brachytherapy, external beam, or both?
If chemotherapy is recommended, what is the regimen and how many cycles?
Am I a candidate for de-escalated treatment based on my molecular profile (e.g., if POLE-mutated)?
What is the expected recovery time, and what restrictions will I have?
If I am premenopausal, what will happen with my hormone levels after surgery, and will I need hormone replacement?

Advanced, Recurrent & Clinical Trials

For patients with advanced or recurrent endometrial cancer, the treatment landscape has changed dramatically. Immunotherapy, combined with standard chemotherapy, has become the new standard of care for first-line treatment — and for patients whose tumors are mismatch repair deficient, the results have been remarkable.

How immunotherapy works here — in plain terms. Immunotherapy drugs called checkpoint inhibitors (such as dostarlimab, pembrolizumab, and durvalumab) release the brakes that cancer puts on your immune system, allowing your own immune cells to recognize and attack the tumor. Added to standard chemotherapy and then continued as maintenance, they have improved survival in advanced endometrial cancer more than any advance in decades. The benefit is greatest for cancers that are mismatch repair deficient (dMMR / MSI-high) — about a quarter of endometrial cancers — where the immune response can be dramatic and long-lasting. This is exactly why testing your tumor’s molecular type matters so much: it tells your team whether you are likely to be one of the patients who benefits most. Immunotherapy also helps many patients whose tumors are not dMMR, just more modestly, and it is now an approved first-line option regardless of MMR status. For cancers that come back after chemotherapy, a combination of lenvatinib plus pembrolizumab is another effective option. These drugs have real side effects — because they activate the immune system, they can occasionally cause it to attack healthy organs — so report new symptoms promptly; most side effects are manageable when caught early.

Targeted treatments and why testing matters. Beyond immunotherapy, some endometrial cancers can be matched to targeted drugs based on specific features: tumors that overproduce a protein called HER2 may respond to HER2-directed therapy; hormone-sensitive (estrogen/progesterone-receptor-positive), low-grade cancers often respond to gentle hormonal pills; and rare genetic changes (such as NTRK fusions) have their own targeted drugs. The common thread is that comprehensive tumor testing — MMR status, p53, HER2, hormone receptors, and broader genetic profiling — opens doors to treatments and clinical trials that simply would not be visible otherwise. If you have advanced or recurrent disease, it is reasonable to confirm that this full testing has been done and to ask whether a clinical trial is a good option for you. Trials are not a last resort; for some patients, a well-matched trial is the best available treatment, and asking about one commits you to nothing.

If the cancer comes back. A recurrence is frightening, but it is not the end of options — and the options today are far better than even a few years ago. Where and how the cancer returns shapes the plan: a recurrence limited to the top of the vagina can sometimes be treated with radiation (if not previously given) with a real chance of long-term control, while a recurrence in more distant sites is usually treated with systemic therapy — immunotherapy, chemotherapy, targeted drugs, or hormonal therapy — chosen based on your tumor’s molecular features. This is exactly why complete molecular testing matters so much at recurrence: it determines which of these doors are open to you. The goals of treatment may shift toward controlling the disease and maintaining quality of life over the long term, and for many women that can mean meaningful, good-quality time. Palliative care — specialized support for symptoms and wellbeing, given alongside cancer treatment — is valuable here and is not the same as giving up. Throughout, a second opinion at an expert gynecologic-cancer center, and asking about clinical trials, are reasonable and often worthwhile steps.

A note for patients and families. A diagnosis of advanced or recurrent endometrial cancer is frightening. But it is important to know that more effective treatment options exist today than at any point in history. Clinical trials continue to push outcomes further. This is not a moment to lose hope — it is a moment to make sure you have access to the best available care.

The current first-line standard for advanced (stage III–IV) or recurrent endometrial cancer combines a checkpoint inhibitor with carboplatin-paclitaxel chemotherapy:

Dostarlimab + carboplatin-paclitaxel (RUBY trial): This combination showed a median overall survival of 44.6 months compared to 28.2 months with chemotherapy alone (hazard ratio 0.69). For patients with dMMR/MSI-high tumors, the benefit was dramatic, with a hazard ratio of 0.32 — meaning the risk of death was reduced by nearly 70%.
Pembrolizumab + carboplatin-paclitaxel (NRG-GY018 / KEYNOTE-868): Another FDA-approved combination showing similar improvements, particularly in the dMMR subgroup.

Both combinations are FDA-approved regardless of MMR status — meaning all patients with advanced endometrial cancer can receive immunotherapy, though the magnitude of benefit is greatest for those with dMMR tumors. Chemotherapy is typically given for 6 cycles, followed by maintenance immunotherapy for up to 3 years or until disease progression.

For patients whose cancer progresses after first-line treatment, the combination of lenvatinib (a multi-kinase inhibitor) plus pembrolizumab (a checkpoint inhibitor) is an established option:

KEYNOTE-775 trial: This combination showed an overall survival hazard ratio of 0.65 across all patients, with 5-year follow-up data reported in 2026 confirming durable benefit.
The combination is effective across all molecular subtypes, including patients with mismatch repair proficient (pMMR) tumors who had fewer options in the past.

Lenvatinib does carry significant side effects (discussed in the Survivorship section), and dose management is important. Many patients require dose reductions, which can maintain efficacy while improving tolerability.

Important distinction. The LEAP-001 trial tested lenvatinib plus pembrolizumab as first-line treatment (instead of chemotherapy) and found it did not outperform carboplatin-paclitaxel. This means lenvatinib-pembrolizumab is a second-line option, not a replacement for first-line immunotherapy plus chemotherapy.

Trastuzumab deruxtecan (T-DXd) for HER2-positive tumors: The DESTINY-PanTumor02 trial showed an overall response rate of 57.5% in HER2-positive endometrial cancer. HER2 testing should be requested for patients with serous carcinoma and other high-grade tumors, where HER2 overexpression is more common.
Selinexor (XPO1 inhibitor) as maintenance therapy: In patients with TP53 wild-type tumors, maintenance selinexor after first-line chemotherapy showed a progression-free survival of 28.4 months compared to 5.2 months with placebo. This agent is not yet FDA-approved specifically for endometrial cancer and is typically available through clinical trials.
Hormonal therapy for low-grade, hormone receptor-positive recurrent disease: Progestins (medroxyprogesterone, megestrol), tamoxifen, aromatase inhibitors (letrozole, anastrozole), or combination approaches can produce durable responses in selected patients with low-grade endometrioid cancers. These are best suited for patients with slow-growing, estrogen- and progesterone-receptor-positive disease.

The RAINBO trial is a landmark international effort testing different adjuvant treatments tailored to each of the four molecular subtypes. It consists of four parallel randomized trials:

POLEmut patients: testing de-escalation (observation vs. standard adjuvant therapy)
dMMR patients: testing the addition of immunotherapy to standard adjuvant treatment
NSMP patients: testing intensification of adjuvant therapy
p53-abnormal patients: testing novel combinations

Results are expected around 2028 and will likely reshape adjuvant treatment guidelines. For now, the trial represents the field’s commitment to treating endometrial cancer according to its molecular biology rather than a one-size-fits-all approach.

Clinical trials are not a last resort — they are often the best available treatment, especially for patients whose cancer has specific molecular features. Here is how to approach them:

Where to search: ClinicalTrials.gov is the most comprehensive database. Search for “endometrial cancer” and filter by your state, phase (Phase II or III for the most developed options), and recruiting status.
Ask your oncologist: Gynecologic oncologists at academic medical centers have the most direct access to trials and can identify which ones match your disease profile.
NCI Cancer Information Service: Call 1-800-4-CANCER for help identifying relevant trials.
GOG Foundation / NRG Oncology: These cooperative groups run most of the major endometrial cancer trials in the United States.

Major trials that shaped current treatment (for reference):

RUBY (ENGOT-EN6/GOG-3031): Dostarlimab + chemotherapy first-line — NCT03981796
NRG-GY018 (KEYNOTE-868): Pembrolizumab + chemotherapy first-line — NCT03914612
KEYNOTE-775 / Study 309: Lenvatinib + pembrolizumab second-line — NCT03517449

Actively enrolling trials to ask your oncologist about:

RAINBO (4 parallel trials): Molecular subtype-guided adjuvant therapy — BLUE arm for POLEmut: NCT05640999
DESTINY-Endometrial01: Trastuzumab deruxtecan for HER2-positive endometrial cancer (Phase 3) — NCT06989112
AtTEnd (ENGOT-EN7): Atezolizumab + chemotherapy in advanced EC — NCT03603184
DUO-E (ENGOT-EN10): Durvalumab + chemotherapy ± olaparib in advanced EC — NCT04269200

Questions to ask about any trial: What is the trial testing? What are the possible benefits and risks? Is there a placebo arm, and if so, what standard treatment will I still receive? What additional appointments, tests, or procedures are required? Will my insurance or the trial cover costs?

When endometrial cancer is advanced or recurrent, the caregiver role becomes more demanding. Some specific guidance:

Help organize treatment schedules, especially when immunotherapy infusions are every 3 or 6 weeks
Track side effects in a daily journal — this information is invaluable at oncology appointments
Learn the signs of immune-related side effects (discussed in the Survivorship section) so you can recognize them early
Attend oncology appointments whenever possible — two sets of ears catch more information
Take care of your own health and emotional needs. Caregiver burnout is real and does not help the patient
Ask the oncology social worker about support groups specifically for caregivers

Is my tumor mismatch repair deficient, and how does that affect my treatment options?
Am I a candidate for immunotherapy plus chemotherapy as first-line treatment?
Has my tumor been tested for HER2 overexpression?
If my cancer progresses on first-line treatment, what are the next options?
Are there any clinical trials at this center or at nearby centers that match my disease profile?
What are the realistic goals of treatment at this point — cure, long-term control, or symptom management?
Should I consider a second opinion at a major gynecologic oncology center?
When should we discuss palliative care to help manage symptoms and quality of life?

Survivorship & Side Effects

Treatment for endometrial cancer can affect nearly every aspect of daily life. Understanding what to expect, knowing how to manage side effects, and building a support structure are essential parts of the journey — not optional extras.

Surgical menopause and hormonal changes. Because surgery removes the ovaries, women who were not yet through menopause will experience it suddenly after the operation — hot flashes, night sweats, mood changes, and vaginal dryness can be more abrupt and intense than natural menopause. These symptoms are real and treatable. Non-hormonal medications, vaginal moisturizers and lubricants, and lifestyle strategies help many women; for some, especially younger women, hormone therapy can be considered, but this decision depends on your cancer type and must be discussed carefully with your team. Do not suffer in silence — raise these symptoms, because effective options exist.

Sexual health, pelvic changes, and lymphedema. Treatment can affect intimacy through vaginal dryness, shortening or narrowing after radiation, and changes in desire or body image. These are common, valid, and addressable: vaginal moisturizers, dilator therapy after pelvic radiation, pelvic-floor physical therapy, and counseling all help, and many cancer centers have specialists for exactly these concerns. If lymph nodes were removed or radiated, watch for lymphedema (swelling, usually in the legs); the risk is much lower now that sentinel-node mapping has replaced extensive node removal, but early attention to swelling, and referral to a lymphedema therapist, makes it far more manageable. Tell your team about any swelling early.

The metabolic and emotional side of recovery. Because obesity, diabetes, and high blood pressure are common in women with endometrial cancer — and affect both recurrence risk and overall health — survivorship is a powerful opportunity to work on weight, blood sugar, physical activity, and heart health, ideally with support from your team or a dietitian. Even modest, sustainable changes help. Just as important is emotional wellbeing: anxiety about recurrence, grief over fertility or body changes, and the stress of treatment are all normal, and counseling, support groups, and (when needed) medication genuinely help. Most women treated for endometrial cancer are cured and go on to live full lives; building healthy routines and tending to your emotional health are how you reclaim that life after treatment.

What follow-up looks like — and the one symptom to never ignore. After treatment, you will have regular check-ups — typically every few months at first, then spacing out over about five years — consisting mainly of conversation and a pelvic examination rather than routine scans, because for most women recurrences are found through symptoms and exam rather than imaging. The single most important thing to report between visits is any new vaginal bleeding, since the top of the vagina is the most common site of recurrence and bleeding there is usually the first clue; new pelvic or abdominal pain, persistent bloating, unexplained weight loss, or a new cough or breathlessness also deserve prompt attention. Knowing this turns follow-up from a source of anxiety into a sense of control: you and your team are partners in watching, and you know exactly what to flag. If you were treated with immunotherapy, your follow-up will also monitor for the immune-related side effects discussed earlier, sometimes for months after treatment ends. Keep your appointments, keep a simple note of any new symptoms, and do not hesitate to call between visits — that is exactly what the team is there for.

For premenopausal women who undergo bilateral oophorectomy, surgical menopause is immediate and can be more intense than natural menopause. Symptoms include hot flashes, night sweats, vaginal dryness, mood changes, difficulty concentrating, sleep disruption, and accelerated bone loss.

Hormone replacement therapy (HRT) after endometrial cancer is a nuanced and sometimes controversial topic:

For early-stage, low-grade endometrioid cancer that has been completely resected, many experts consider systemic HRT a reasonable option, particularly for younger women whose quality of life is significantly impacted.
For high-grade, advanced, or non-endometrioid cancers, HRT is generally avoided due to theoretical concerns about hormone-sensitive disease.
Vaginal estrogen (a low-dose, locally acting formulation) is often considered safe even when systemic HRT is not recommended, though this should be discussed with your oncologist.

Non-hormonal alternatives for managing menopausal symptoms include SSRIs/SNRIs (venlafaxine, paroxetine), gabapentin, cognitive behavioral therapy for insomnia, regular exercise, and cooling strategies for hot flashes.

For caregivers. Surgical menopause can cause sudden and significant changes in mood, sleep, and comfort. Understanding that these symptoms have a physiological cause — and that they are not a reflection of the patient’s coping ability — helps maintain a supportive home environment. Patience, practical help with sleep disruption, and gentle encouragement to discuss symptoms with the medical team all make a meaningful difference.

Lymphedema — chronic swelling, usually in the legs — is a risk after lymph node removal. The risk is substantially lower with sentinel lymph node mapping compared to full lymphadenectomy.

Prevention: Maintain a healthy weight, stay physically active, avoid prolonged sitting or standing, protect the legs from cuts and infections, and consider referral to a lymphedema therapist if early signs appear (heaviness, tightness, mild swelling).
Treatment: Complete decongestive therapy (CDT) is the gold standard — a combination of manual lymphatic drainage, compression garments, exercise, and skin care. Early intervention produces the best results.
When to seek help: Any new swelling, heaviness, or tightness in one or both legs that persists for more than a few days should be reported to the medical team.

Checkpoint inhibitors (dostarlimab, pembrolizumab) work by unleashing the immune system against cancer. However, an activated immune system can also attack healthy tissues. These immune-related adverse events (irAEs) can affect virtually any organ:

Colitis: Diarrhea (more than 3 loose stools per day), abdominal pain, blood in stool. Report promptly.
Hepatitis: Often detected on blood tests before symptoms appear. Regular liver function tests are standard during treatment.
Thyroid disorders: Hypothyroidism (fatigue, weight gain, feeling cold) or hyperthyroidism (anxiety, rapid heart rate, weight loss). Managed with thyroid hormone replacement.
Pneumonitis: New or worsening cough, shortness of breath. Requires prompt evaluation.
Skin reactions: Rash, itching. Usually manageable with topical treatments.
Adrenal insufficiency: Fatigue, dizziness, nausea. Can be life-threatening if not recognized.

The most important principle: report any new or worsening symptom to the oncology team promptly. Most irAEs are manageable when caught early, usually with corticosteroids. The immunotherapy may need to be paused or, in severe cases, permanently discontinued.

Lenvatinib, used in combination with pembrolizumab for recurrent disease, has a distinct side effect profile:

Hypertension: Very common. Blood pressure monitoring at home and antihypertensive medications are usually required.
Diarrhea: Often manageable with loperamide and dietary adjustments.
Fatigue: Can be significant. Pacing activities and maintaining gentle exercise helps.
Hand-foot syndrome (palmar-plantar erythrodysesthesia): Redness, swelling, and pain on palms and soles. Moisturizing, avoiding friction, and dose adjustments are key.
Decreased appetite and weight loss: Small, frequent, calorie-dense meals and nutrition counseling are helpful.
Hypothyroidism: Regular thyroid function testing and replacement as needed.
Proteinuria: Monitored with urine tests during treatment.

Dose reductions are common and expected with lenvatinib — studies show that reduced doses maintain efficacy while significantly improving quality of life. Do not hesitate to discuss dose adjustments with the oncologist.

Carboplatin-paclitaxel chemotherapy:

Peripheral neuropathy: Tingling, numbness, or pain in hands and feet, caused primarily by paclitaxel. May persist after treatment ends. Report early worsening so dose adjustments can be made.
Fatigue: Often cumulative, worsening with each cycle. Plan for reduced activity during treatment weeks.
Hair loss (alopecia): Usually begins 2–3 weeks after the first cycle. Hair typically regrows after treatment ends.
Low blood counts: Increased infection risk (neutropenia), bleeding risk (thrombocytopenia), and anemia. Blood counts are monitored before each cycle.
Nausea: Usually well controlled with modern anti-nausea medications given before each infusion.

Radiation therapy:

Vaginal stenosis: Narrowing and shortening of the vagina. Use of a vaginal dilator, as instructed by the radiation team, helps prevent this and should begin 2–4 weeks after treatment.
Bladder irritation: Frequency, urgency, burning with urination. Usually temporary.
Bowel changes: Diarrhea, urgency, cramping. Dietary modifications and medications can help.
Fatigue: Gradually builds during the treatment course and resolves over weeks to months afterward.

The impact of endometrial cancer treatment on sexual health is real and deserves honest attention. Surgery, radiation, and hormonal changes can all affect sexual function:

Vaginal dryness: Caused by surgical menopause and/or radiation. Vaginal moisturizers (used regularly) and lubricants (used during intimacy) are the first-line approach. Vaginal estrogen may be appropriate for some patients.
Vaginal stenosis: After radiation, regular use of a vaginal dilator (typically 3 times per week) helps maintain vaginal length and flexibility.
Changes in desire and arousal: Hormonal changes, fatigue, body image concerns, and emotional distress can all contribute. These are normal responses to treatment, not personal failures.
Body image: Surgical scars, weight changes, and hair loss can affect how a woman sees herself. Counseling, support groups, and honest conversation with partners all help.

Ask the medical team for a referral to a sexual health specialist or pelvic floor physical therapist. These issues are common, treatable, and nothing to be embarrassed about.

For women who have not completed their families, or who find meaning in their reproductive identity, the loss of the uterus and ovaries can trigger genuine grief. This is true even when the surgery is life-saving and the patient is intellectually at peace with the decision.

This grief is valid and deserves acknowledgment — from the medical team, from family, and from the patient herself.
Counseling with a therapist who understands oncofertility and reproductive loss can be profoundly helpful.
Connecting with other women who have experienced similar loss (through support groups or online communities) reduces isolation.
The grief may surface at unexpected times — at a friend’s pregnancy announcement, during holidays, years after treatment. This is normal.

For caregivers. Do not minimize the emotional impact of reproductive loss by focusing only on the cancer outcome. “At least the cancer is gone” is true but incomplete. Acknowledge that two things can be true at once: relief that treatment worked and grief for what was lost. Simply listening without trying to fix the feelings is often the most helpful response.

Because obesity is such a strong risk factor for endometrial cancer (and for recurrence), addressing weight and lifestyle after treatment is clinically important — not optional. Evidence-based approaches include:

Exercise: At least 150 minutes per week of moderate-intensity activity (such as brisk walking). Exercise reduces recurrence risk, manages fatigue, improves mood, and helps with weight control.
Nutrition: Focus on a plant-forward diet rich in vegetables, fruits, whole grains, and lean protein. Limit processed foods, added sugars, and alcohol. A referral to an oncology dietitian is valuable.
Weight management programs: For patients with obesity, structured weight loss programs, and in some cases GLP-1 receptor agonist medications (such as semaglutide), may be appropriate. Discuss with the medical team.
Diabetes management: Optimizing blood sugar control is important for overall health and may influence cancer outcomes.

After completing treatment, regular follow-up visits monitor for recurrence and manage long-term side effects. The typical schedule:

Years 1–2: Visits every 3–4 months. History, physical exam, and pelvic exam. Vaginal cytology (Pap smear of the vaginal cuff) may be performed at some centers.
Years 3–5: Visits every 6 months.
After 5 years: Annual visits.

Imaging (CT scans) is not routinely performed at every visit unless there are symptoms or specific concerns. CA-125 may be monitored in patients whose levels were elevated at diagnosis, particularly those with serous carcinoma.

The most important surveillance tool is symptom awareness. Report any new vaginal bleeding, unexplained pelvic or abdominal pain, persistent cough, or unexplained weight loss promptly.

What follow-up schedule do you recommend for my specific situation?
Am I a candidate for hormone replacement therapy to manage menopausal symptoms?
What should I do to reduce my risk of lymphedema?
When should I start using a vaginal dilator after radiation, and how often?
Are there resources for managing sexual health concerns after treatment?
Should I see an oncology dietitian or consider a structured weight management program?
What symptoms should prompt me to call between scheduled visits?
Do I need bone density screening given my surgical menopause?
Can you refer me to a counselor or support group for emotional support?

Support & Resources

No one should navigate endometrial cancer alone. The resources below span local institutions in Utah, national organizations, clinical trial databases, financial assistance, and emotional support. Reach out early — these services exist specifically for patients and families in your situation.

Practical and financial help exists — use it. Cancer care is expensive and logistically demanding even when treatment goes smoothly, and asking for help is a sign of good self-advocacy, not weakness. Most cancer centers have oncology social workers and financial navigators whose entire job is to help with insurance questions, treatment costs, transportation, lodging if you travel for care, and time off work — ask to be connected with them early. National organizations focused on gynecologic cancers (such as the Foundation for Women’s Cancer and SHARE) offer free education, helplines, and peer support that pairs you with someone who has been through it. Drug-manufacturer patient-assistance programs and copay foundations can substantially reduce the cost of immunotherapy and targeted drugs. If you are working, learn your rights regarding medical leave, and keep an organized folder of bills and records to catch errors and support appeals. For caregivers, respite and support resources matter too — sustained caregiving is easier when the load is shared and supported.

For younger women diagnosed with early, low-grade cancer. A small number of women diagnosed before they have completed their families — with very early, low-grade, hormone-sensitive cancer confined to the uterine lining — may be candidates for fertility-sparing treatment, using hormonal therapy (progestin pills or a progestin-releasing IUD) to try to reverse the cancer while preserving the uterus, with close monitoring by repeat biopsies. This is a specialized, carefully selected option with real trade-offs — it is not standard, it requires strict follow-up, there is a genuine risk the cancer persists or returns, and surgery is still recommended once childbearing is complete. If preserving fertility matters to you, raise it early and ask for referral to a gynecologic oncologist (and a fertility specialist) experienced in this approach, so the decision can be made with full information and a realistic plan toward a healthy pregnancy.

For partners, family, and caregivers. Supporting someone through endometrial cancer is its own role, and doing it well starts with a few practical things. Come to key appointments if you can — an extra set of ears helps capture information and questions when the patient is overwhelmed — and keep a shared list of medications, contacts, and upcoming dates. Practical help is often what is needed most: rides to treatment, meals, childcare, and help with everyday tasks during recovery from surgery. Be aware that this cancer and its treatment can bring abrupt menopause, sexual-health changes, and emotional strain; gentle, non-judgmental openness about these topics matters, and so does patience. Watch for signs that your loved one is struggling emotionally — withdrawal, persistent sadness, or anxiety — and encourage professional support, which is a strength, not a failure. And protect your own wellbeing too: caregiver fatigue is real, and most cancer centers offer support services, counseling, and respite resources for caregivers as well as patients. Sharing the load and asking for help early makes the whole journey more sustainable for both of you.

>Specialty Center Directory

Centers with gynecologic oncology expertise relevant to endometrial cancer, organized by region. Contact information is provided to help you start the referral process.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

Huntsman Cancer Institute (University of Utah)

NCI-designated Comprehensive Cancer Center — the highest NCI designation

Program: Gynecologic Oncology Program with dedicated endometrial cancer multidisciplinary tumor board (gynecologic oncology, radiation oncology, medical oncology, pathology, radiology, genetics)
Phone: 801-585-0303 (patient referrals) | 801-587-7000 (main line)
Clinical trials: Active enrollment in NRG Oncology/GOG cooperative group trials and industry-sponsored immunotherapy and targeted therapy studies for endometrial cancer. Trial inquiries: 801-587-4765.
Molecular testing: Full endometrial cancer molecular classification panel (MMR IHC, p53 IHC, POLE sequencing, HER2 IHC/FISH, ER/PR) through ARUP Laboratories
Genetic counseling: Comprehensive Lynch syndrome evaluation and family cascade testing
Website: healthcare.utah.edu/huntsmancancerinstitute

University of Utah Health

Phone: 801-581-2121 (main)
Genetic Counseling: For Lynch syndrome screening, germline testing, and cascade testing of at-risk family members. Phone: 801-585-7300.
ARUP Laboratories: National reference laboratory headquartered at U of U — comprehensive molecular testing for endometrial cancer

Intermountain Health

Integrated nonprofit health system — broad geographic reach across Utah, Idaho, Nevada, Colorado, and Montana

Program: Gynecologic oncology care at Intermountain Medical Center (Murray), McKay-Dee Hospital (Ogden), and regional clinics
Phone: 801-442-2000 (main system line)
Precision Genomics: Intermountain Precision Genomics offers tumor molecular profiling and clinical trial matching
Community access: Extensive cancer center network throughout Utah and surrounding states, improving access for rural patients

How to choose. Huntsman Cancer Institute = NCI comprehensive cancer center with full clinical trials portfolio, molecular pathology through ARUP, Lynch syndrome genetics program, and multidisciplinary tumor boards. Best for complex cases, clinical trial access, rare histologies, and second opinions. Intermountain = community-based gynecologic oncology with broad geographic access, often in-network. Good for patients who need quality care closer to home. VA Wahlen (below) = eligible veterans with VA benefits.

MD Anderson Cancer Center

Location: Houston, TX · Phone: 877-632-6789
One of the largest gynecologic oncology programs nationally. Extensive endometrial cancer clinical trials portfolio including molecular-guided therapy studies.

Memorial Sloan Kettering Cancer Center

Location: New York, NY · Phone: 212-639-2000
Major gynecologic oncology program with pioneering sentinel lymph node mapping research and molecular classification expertise.

Mayo Clinic

Location: Rochester, MN · Phone: 507-538-3270
Comprehensive gynecologic oncology program with national reach. Leading clinical trials and molecular pathology capabilities.

Dana-Farber Cancer Institute

Location: Boston, MA · Phone: 617-632-3000
Harvard-affiliated. Strong immunotherapy and targeted therapy research in endometrial cancer.

Johns Hopkins Kimmel Cancer Center

Location: Baltimore, MD · Phone: 410-955-8964
Gynecologic oncology program with expertise in hereditary cancer syndromes and molecular classification.

George E. Wahlen VA Medical Center

Location: 500 Foothill Dr, Salt Lake City, UT 84148
Phone: 801-582-1565
Women veterans with endometrial cancer can receive gynecologic oncology care through the VA system, with referrals to Huntsman Cancer Institute or Intermountain Health for specialized surgical and trial access when needed.

VA note. Female veterans are the fastest-growing segment of the veteran population. The VA provides gynecologic cancer care and can coordinate with NCI-designated cancer centers for complex cases. Contact the Women Veterans Program Manager at your local VA for coordination.

Princess Margaret Cancer Centre

Location: Toronto, ON · Phone: 416-946-4501
One of the top five cancer centers globally. Major gynecologic oncology program with endometrial cancer clinical trials, molecular classification, and Lynch syndrome genetics.

Sunnybrook Odette Cancer Centre

Location: Toronto, ON · Phone: 416-480-4998
Gynecologic oncology program with brachytherapy expertise and clinical trial access.

McGill University Health Centre (MUHC)

Location: Montreal, QC · Phone: 514-934-1934
Bilingual gynecologic oncology program with clinical trials and molecular pathology through the McGill Genome Centre.

BC Cancer — Vancouver Centre

Location: Vancouver, BC · Phone: 604-877-6000
Provincial cancer program with gynecologic cancer specialists, molecular testing, and clinical trial enrollment. Part of BC Cancer’s provincial network.

The Christie NHS Foundation Trust

Location: Manchester, UK · Phone: +44 161 446 3000
One of Europe’s largest cancer centers. Major gynecologic oncology program with RAINBO trial enrollment and molecular classification expertise.

Leiden University Medical Center (LUMC)

Location: Leiden, Netherlands
Home of the PORTEC trial series and TransPORTEC molecular classification. Leading international center for molecular-guided endometrial cancer treatment.

National Cancer Center Japan

Location: Tokyo, Japan · Phone: +81 3-3542-2511
Leading Asian center for gynecologic oncology with access to JSGO-guided clinical trials and molecular classification programs.

Institut Gustave Roussy

Location: Villejuif (Paris), France · Phone: +33 1 42 11 42 11
Europe’s largest cancer center. Major ENGOT trial network participant with extensive endometrial cancer research and molecular pathology programs.

Foundation for Women’s Cancer (FWC): The official foundation of the Society of Gynecologic Oncology. Provides patient education, support programs, and research funding for gynecologic cancers. Website: foundationforwomenscancer.org
Society of Gynecologic Oncology (SGO): The premier professional society for gynecologic cancer specialists. Their patient resources page provides vetted educational materials. Website: sgo.org
GOG Foundation: A leading organization conducting clinical trials in gynecologic cancers. Information about open trials and eligibility is available on their website. Website: gog.org
NRG Oncology: A National Cancer Institute-supported clinical trials group that runs many of the major endometrial cancer trials. Website: nrgoncology.org
National Cancer Institute (NCI): Comprehensive cancer information, clinical trial search, and the Cancer Information Service (1-800-4-CANCER). Website: cancer.gov
American Cancer Society: Provides practical support including transportation, lodging, and 24/7 helpline (1-800-227-2345). Website: cancer.org

ClinicalTrials.gov: The most comprehensive database of clinical trials worldwide. Search for “endometrial cancer” or “uterine cancer” and filter by location, phase, and recruiting status. Website: clinicaltrials.gov
NCI Cancer Information Service: Call 1-800-4-CANCER for personalized help identifying clinical trials that match your diagnosis.
Gynecologic Oncology Group (GOG) / NRG Oncology trials: Your gynecologic oncologist can check whether you are eligible for any active GOG or NRG trials.
Huntsman Cancer Institute Clinical Trials: One of the largest clinical trials programs in the Mountain West region. Phone: 801-587-4765.

Cancer treatment can create significant financial strain. Resources that may help:

Hospital financial counselors: Every major cancer center has financial counselors who can help with insurance navigation, co-pay assistance, and charity care applications. Ask for a referral at your first visit.
Patient Access Network Foundation (PAN): Provides co-pay assistance for insured patients. Website: panfoundation.org
CancerCare: Offers limited financial assistance for treatment-related costs, co-pays, and transportation. Phone: 1-800-813-4673. Website: cancercare.org
Pharmaceutical company patient assistance programs: Most companies that manufacture immunotherapy and targeted therapy drugs offer programs for uninsured or underinsured patients. Your oncology team or pharmacist can help with applications.
Social Security Disability Insurance (SSDI): Endometrial cancer may qualify for expedited processing through the Compassionate Allowances program, depending on stage and histology.

Oncology social workers: Available at most cancer centers. They provide counseling, connect patients and families with community resources, and help navigate the practical and emotional challenges of treatment.
Cancer Support Community: Provides free professional support services including counseling, support groups, and educational workshops. Phone: 1-888-793-9355. Website: cancersupportcommunity.org
Online peer communities: Organizations like Inspire and the Endometrial Cancer Support Group on social media platforms connect patients who share similar diagnoses. Peer support can reduce isolation and provide practical tips from those who have been through similar experiences.
Palliative care: A specialized medical discipline focused on quality of life — symptom management, emotional support, and help with difficult decisions. Palliative care is appropriate at any stage of disease, not only at end of life. Ask for a referral early.
Mental health professionals: Psychologists and psychiatrists who specialize in oncology understand the unique emotional terrain of cancer. Anxiety, depression, grief about fertility loss, and fear of recurrence are all common and treatable.

Caregiving during cancer treatment is demanding, and caregiver burnout is well documented. It is not selfish to attend to your own needs — it is necessary.

Ask for and accept help. Specific asks (“Can you bring dinner on Tuesday?”) are easier for others to say yes to than vague offers.
Maintain your own medical appointments. Caregivers who neglect their own health become patients themselves.
Connect with other caregivers. CancerCare offers free caregiver support groups (1-800-813-4673). The Cancer Support Community also has caregiver-specific resources.
Set boundaries. You cannot be everything to everyone. Identify which tasks you can do, which you can delegate, and which can wait.
Seek professional support. A few sessions with a therapist experienced in caregiver stress can provide tools for managing the emotional load.

Caregiver note. If you are supporting someone with endometrial cancer, know that your presence matters more than your expertise. You do not need to have all the answers. Showing up, listening, driving to appointments, sitting in waiting rooms, and simply being there — these are the things patients remember and value most.

Can you connect me with a financial counselor to help with treatment costs?
Is there an oncology social worker I can speak with?
Do you have support groups for women with endometrial cancer?
Can you refer me to genetic counseling for Lynch syndrome evaluation?
Are there clinical trials available at this center that I should consider?
Can you recommend a mental health professional who works with cancer patients?
What palliative care services are available, and when should I consider a referral?
Are there survivorship programs that can help me transition from active treatment to long-term follow-up?

International Access & Regulatory Landscape

Endometrial cancer treatment and drug availability vary by country and regulatory body. Understanding what is approved where — and where guidelines differ — can help you have informed conversations with your medical team, especially if you are seeking treatment outside your home country.

Dostarlimab (Jemperli) + carboplatin-paclitaxel: FDA-approved July 2023 for primary advanced or recurrent endometrial cancer that is dMMR or MSI-H (RUBY trial). Expanded August 2024 to include all-comer advanced/recurrent EC regardless of MMR status.
Pembrolizumab (Keytruda) + carboplatin-paclitaxel: FDA-approved June 2024 for primary advanced or recurrent endometrial cancer (all-comer; NRG-GY018/KEYNOTE-868).
Durvalumab (Imfinzi) + carboplatin-paclitaxel, then durvalumab ± olaparib maintenance: FDA-approved June 2024 for primary advanced or recurrent dMMR endometrial cancer (DUO-E trial). The olaparib-containing maintenance arm is an additional option in this setting.
Lenvatinib + pembrolizumab (Lenvima + Keytruda): FDA-approved (accelerated 2019; full July 2021) for advanced endometrial cancer that has progressed after prior systemic therapy and is not MSI-H or dMMR (i.e., pMMR). This indication remains restricted to pMMR/not-MSI-H disease — it was not expanded to all-comers.
Dostarlimab (single agent): FDA-approved for dMMR recurrent/advanced EC that progressed on or after prior platinum-based chemotherapy.
Trastuzumab deruxtecan (Enhertu): FDA-approved via the tumor-agnostic DESTINY-PanTumor02 pathway for HER2-positive (IHC 3+) solid tumors, including endometrial cancer.

Dostarlimab + carboplatin-paclitaxel: EMA-approved for dMMR/MSI-H advanced or recurrent EC. NICE has issued positive guidance for NHS use in this population.
Pembrolizumab + carboplatin-paclitaxel: EMA marketing authorization for primary advanced or recurrent EC. NICE appraisal ongoing for broader access.
Lenvatinib + pembrolizumab: EMA-approved for previously treated advanced EC. NICE recommends this combination for patients after prior systemic therapy.
Key difference from US: The ESMO-ESGO-ESTRO guidelines formally integrate molecular classification into risk stratification more explicitly than NCCN, and this approach directly determines adjuvant therapy recommendations in European practice.

Dostarlimab: Approved for dMMR/MSI-H advanced or recurrent EC.
Pembrolizumab: Approved for MSI-H solid tumors (tumor-agnostic indication covering EC) and in combination with lenvatinib for previously treated advanced EC.
Lenvatinib + pembrolizumab: Approved for advanced EC after prior systemic therapy. Lenvatinib was originally developed in Japan.
Molecular testing: Adoption of full TCGA-based molecular classification is increasing at major centers. The Japanese Society of Gynecologic Oncology (JSGO) guidelines incorporate molecular testing recommendations.

Dostarlimab + carboplatin-paclitaxel: Health Canada-approved for dMMR/MSI-H primary advanced or recurrent EC.
Pembrolizumab + lenvatinib: Approved for advanced EC after prior systemic therapy.
Provincial access: Drug coverage varies by province. Pan-Canadian Oncology Drug Review (pCODR) recommendations guide provincial formulary listings, but there can be delays between federal approval and provincial coverage.
Molecular testing: Widely available through provincial reference laboratories. Universal MMR testing is standard practice across Canada.

Dostarlimab + carboplatin-paclitaxel: TGA-approved for dMMR/MSI-H advanced or recurrent EC. Listed on the Pharmaceutical Benefits Scheme (PBS) for this indication.
Lenvatinib + pembrolizumab: TGA-approved for previously treated advanced EC.
Trastuzumab deruxtecan: TGA-approved for HER2-positive solid tumors via the tumor-agnostic pathway.
Key consideration: PBS listing determines out-of-pocket cost for Australian patients. Some newer combinations may have TGA approval but delayed PBS listing, creating significant cost barriers.

Molecular classification integration: ESMO-ESGO-ESTRO (Europe) formally integrates molecular classification into risk stratification and adjuvant treatment decisions. NCCN (US) encourages molecular testing but has not yet restructured risk groups around molecular subtypes to the same degree.
Adjuvant therapy de-escalation: European guidelines are more accepting of de-escalation for POLE-mutated tumors (potentially omitting adjuvant therapy entirely). NCCN is more conservative, recommending molecular data be considered alongside traditional factors.
Sentinel lymph node mapping: NCCN lists SLN mapping as the preferred staging approach. ESMO-ESGO-ESTRO considers it an acceptable alternative to full lymphadenectomy. Both agree it reduces morbidity.
FIGO 2023 staging: The updated FIGO staging system (incorporating molecular data) is recognized globally but adoption speed varies. Not all institutions have fully implemented the molecular notations.

Failed & De-Adopted Therapies

Knowing what has been tried and did not work is just as important as knowing what does work. If someone recommends one of these approaches, it is worth discussing the evidence with your medical team. Science advances by learning from what fails.

Routine full pelvic and para-aortic lymphadenectomy for early-stage disease DE-ADOPTED
Two large randomized trials (ASTEC and an Italian trial by Benedetti Panici et al.) showed that removing all pelvic lymph nodes did not improve overall survival in early-stage endometrial cancer, while significantly increasing surgical complications and lymphedema. Sentinel lymph node mapping is now the preferred approach.
Whole-abdomen radiation therapy (WART) DE-ADOPTED
Once used for advanced-stage endometrial cancer, GOG-122 demonstrated that chemotherapy (cisplatin + doxorubicin) was superior to whole-abdomen irradiation for advanced EC. WART has been abandoned in favor of systemic chemotherapy with or without targeted radiation.
Bevacizumab (Avastin) as single agent or in first-line combinations FAILED
Despite showing modest single-agent activity, bevacizumab did not demonstrate sufficient benefit in endometrial cancer to gain regulatory approval for this indication. It was studied in GOG-86P and other trials but was superseded by immunotherapy-based combinations with far greater efficacy.
LEAP-001: Lenvatinib + pembrolizumab as first-line therapy FAILED
The LEAP-001 trial tested lenvatinib + pembrolizumab against standard carboplatin-paclitaxel chemotherapy as first-line treatment for advanced EC. It did not meet its primary endpoint — the combination was not superior to standard chemotherapy in the first-line setting. The lenvatinib + pembrolizumab combination remains approved and effective in the second-line setting only.
High-dose progestin therapy for advanced or recurrent high-grade disease DE-ADOPTED
Medroxyprogesterone acetate and megestrol acetate were once widely used for advanced and recurrent endometrial cancer. Response rates in high-grade and non-endometrioid tumors are very low (under 10%), and randomized data showed no survival benefit. Progestins remain appropriate only for low-grade, hormone receptor-positive disease or in the fertility-sparing setting.
Single-agent cisplatin for advanced disease DE-ADOPTED
Cisplatin alone was used historically but was shown to be inferior to multi-agent chemotherapy. GOG-177 demonstrated that the three-drug combination of cisplatin, doxorubicin, and paclitaxel was superior to cisplatin plus doxorubicin, and subsequent trials established carboplatin-paclitaxel as the preferred doublet due to a better toxicity profile.
mTOR inhibitors as single agents (temsirolimus, ridaforolimus) FAILED
Despite the PI3K/AKT/mTOR pathway being one of the most commonly altered in endometrial cancer, single-agent mTOR inhibitors (temsirolimus in GOG-248, ridaforolimus) showed only modest and transient responses. These agents have not advanced to approval for EC. Combination strategies targeting this pathway remain under investigation.

Why this matters: If you encounter a recommendation for any of these approaches, ask your oncologist about the current evidence. Medicine evolves, and what was standard practice years ago may have been replaced by more effective options.

Honest Uncertainties

Good medical guides should be transparent about what is not yet known. These are some of the open questions in endometrial cancer that researchers and clinicians are actively working to resolve.

Naming these uncertainties is not meant to unsettle you — it is meant to help you ask good questions and understand why your doctors sometimes say “we think” rather than “we know.” The encouraging context is that nearly all of these open questions exist because the field is moving so fast: molecular classification, immunotherapy, and de-escalation strategies are all so new that researchers are still mapping their full potential. For you as a patient, the practical implication is steady: the established foundations — prompt evaluation of abnormal bleeding, surgery by a gynecologic oncologist, molecular testing, and the now-standard treatments — are well proven, and the uncertainties mostly concern how to do even better. Where a question directly affects your choices (for example, whether you can safely have less treatment, or whether a clinical trial is right for you), it is entirely appropriate to discuss the current evidence and the trade-offs openly with your team, and to seek a second opinion at an expert center when a decision feels finely balanced.

Optimal adjuvant therapy for each molecular subtype: The RAINBO trial (results expected ~2028) is testing subtype-specific adjuvant strategies, but until then, treatment decisions rely on extrapolation from existing trials that did not stratify by molecular classification.
How far to de-escalate treatment for POLE-mutated tumors: These patients do so well that many experts believe some can safely skip adjuvant therapy entirely. But the evidence to confirm this is still maturing.
The role of immunotherapy in earlier-stage disease: Current approvals are for advanced/recurrent disease. Whether adding immunotherapy to adjuvant treatment for high-risk early-stage patients improves outcomes is under active investigation.
Long-term effects of immunotherapy: Checkpoint inhibitors have been used in endometrial cancer for only a few years. Very long-term side effects and quality-of-life impacts are still being characterized.
Why endometrial cancer is rising in younger women: While obesity explains much of the overall increase, the reasons for rising incidence in women under 50 are not fully understood.
HRT safety after endometrial cancer: The safety of hormone replacement therapy after treatment for early-stage, low-grade disease remains debated. No large randomized trial has definitively answered this question.
Optimal use of ctDNA (circulating tumor DNA): Blood-based tests for residual cancer are being studied but are not yet standard of care for treatment decisions in endometrial cancer.

Acknowledging these uncertainties is not a weakness — it is a sign of intellectual honesty. The medical team should be willing to discuss what is known, what is probable, and what remains uncertain.

Glossary

Key terms used throughout this guide, explained in plain language.

Adjuvant therapy: Treatment given after surgery to reduce the risk of cancer coming back. May include chemotherapy, radiation, or immunotherapy.
Bilateral salpingo-oophorectomy (BSO): Surgical removal of both ovaries and both fallopian tubes.
Brachytherapy: Radiation delivered internally, directly to the target area. In endometrial cancer, vaginal brachytherapy delivers radiation to the vaginal cuff.
Carcinosarcoma: An aggressive type of uterine cancer containing both carcinoma and sarcoma elements.
Checkpoint inhibitor: A type of immunotherapy drug that removes the “brakes” on the immune system, allowing it to attack cancer cells. Examples: dostarlimab, pembrolizumab.
dMMR (mismatch repair deficient): A tumor that has lost the ability to repair certain DNA errors. These tumors respond well to immunotherapy.
Endometrioid: The most common histologic type of endometrial cancer, arising from glandular cells.
FIGO staging: The staging system used internationally for gynecologic cancers, developed by the International Federation of Gynecology and Obstetrics.
Hysterectomy: Surgical removal of the uterus. A total hysterectomy also removes the cervix.
Immune-related adverse event (irAE): A side effect of immunotherapy caused by the immune system attacking healthy tissues.
Lymphedema: Chronic swelling, usually in the legs, caused by damage to or removal of lymph nodes.
Lynch syndrome: An inherited genetic condition that significantly increases the risk of endometrial, colon, ovarian, and other cancers.

MSI-high (microsatellite instability-high): A molecular feature of tumors with mismatch repair deficiency. Detected by testing the tumor tissue.
Myometrial invasion: How deeply the tumor has grown into the muscular wall of the uterus. Deeper invasion indicates higher risk.
NSMP (no specific molecular profile): The most common molecular subtype of endometrial cancer, defined by the absence of POLE mutations, MMR deficiency, and p53 abnormalities.
p53-abnormal: A molecular subtype associated with mutations in the TP53 gene. Tends to be the most aggressive subtype.
Palliative care: Medical care focused on quality of life and symptom management. Appropriate at any stage of disease, not only end of life.
POLE-mutated (POLEmut): A molecular subtype with mutations in the POLE gene. Despite having many mutations, these tumors have the best prognosis.
Sentinel lymph node (SLN): The first lymph node(s) to which cancer cells are most likely to spread from the primary tumor.
Serous carcinoma: An aggressive histologic type of endometrial cancer, often associated with p53-abnormal molecular classification.
Vaginal cuff: The closed top of the vagina after hysterectomy, where the cervix was previously attached.
Vaginal stenosis: Narrowing and shortening of the vagina, which can occur as a side effect of radiation therapy.

Appendix — Emerging Science

Testing Treatments on a Copy of Your Own Tumor

Endometrial cancer is one of the best candidates for functional tumor testing — a field where researchers grow living copies of a patient's cancer in the lab and use them to predict which drugs are most likely to work before those drugs are given to the patient. The reason endometrial cancer fits so well is straightforward: the biopsy your doctor already performs to diagnose this cancer — usually a quick office procedure or a D&C in the hospital — collects more than enough tissue to run these experiments. There is no separate surgery needed, no extra waiting, and no additional risk. For many other cancers, getting enough usable tissue is a major practical obstacle. For endometrial cancer, that obstacle is much smaller, which is why researchers have been actively building and studying endometrial cancer models since at least 2017.

Beyond tissue access, endometrial cancer is molecularly diverse in ways that make drug prediction genuinely valuable. Two people with the same stage and grade of endometrial cancer may respond very differently to the same treatment because their tumors have different underlying biology. Functional testing aims to capture that individual biology in the lab so that treatment decisions can be better informed by what your specific tumor actually does — not just what tumors like it tend to do on average.

Most important thing to know: Functional tumor testing for endometrial cancer is investigational. It is not a standard part of care and is not yet covered by most insurance plans for this purpose. Research programs and clinical trials are expanding, but at this time, functional testing is a supplement to — not a replacement for — the molecular testing and treatment planning your oncology team already performs. Decisions about your treatment should be made with your oncologist based on current evidence-based guidelines.

The basic idea

Every endometrial tumor has a biological fingerprint shaped by the mutations it carries, the hormones it responds to, and the immune signals it sends out. Oncologists already use molecular profiling — looking at markers like mismatch repair status, POLE mutations, and HER2 amplification — to guide treatment decisions. But molecular profiling tells you what the tumor looks like genetically. Functional testing tells you what the tumor actually does when it encounters a drug. Those two pieces of information are related but not identical. A tumor might carry a mutation that is associated with drug sensitivity in theory, yet still fail to respond in practice because of other biological factors not captured by the genetic test.

This gap matters especially in endometrial cancer because treatment has grown more complex. The standard carboplatin-paclitaxel chemotherapy backbone is now combined with immunotherapy (pembrolizumab or dostarlimab for dMMR tumors; lenvatinib plus pembrolizumab for others), HER2-targeted agents for serous subtypes, and hormonal therapies such as progestins and aromatase inhibitors for select patients who want to preserve fertility or cannot tolerate intensive chemotherapy. Each of these pathways behaves differently across the four molecular subtypes identified by The Cancer Genome Atlas — POLE-mutated, MSI-H/dMMR, copy-number high, and copy-number low. Functional testing in living tumor tissue has the potential to reveal which combination is most likely to work for a specific patient, particularly in recurrent or advanced disease where choosing wisely matters most.

The main approaches, from fastest to slowest

Tumor organoids

Turnaround: 3–6 weeks | Tissue needed: Small biopsy or D&C specimen | Most studied for endometrial cancer

Organoids are three-dimensional, self-organizing clusters of cancer cells grown in a gel matrix that mimics the environment inside the body. For endometrial cancer, organoids have been under active development since around 2017, and published laboratory studies report establishment success rates of roughly 70 to 85 percent from standard diagnostic specimens — including Pipelle office biopsies, D&C samples, and hysterectomy tissue. That success rate is meaningfully higher than for many other cancer types, which typically require more invasive biopsies to obtain enough viable cells.

Once established, endometrial organoids can be treated with individual drugs or combinations and observed over days to weeks. Notably, they can be tested with hormonal agents — progestins, aromatase inhibitors — in addition to standard chemotherapy and targeted agents, which is an advantage unique to hormone-sensitive cancers like endometrial. Researchers at several centers have used endometrial organoids to study how tumor cells respond to immunotherapy sensitizers and to explore why some tumors resist pembrolizumab despite appearing microsatellite unstable on standard testing. The cultures require specialized endometrial media formulations and careful quality control to maintain tumor characteristics over time. Results are reported as a drug sensitivity profile, usually expressed as the drug concentration required to reduce tumor cell viability by a set percentage.

Zebrafish avatars

Turnaround: 1–2 weeks | Tissue needed: Small biopsy fragment | Speed advantage for urgent decisions

In the zebrafish avatar approach, dissociated tumor cells from a patient's biopsy are injected into zebrafish embryos, which are then treated with different drug regimens. Because zebrafish embryos develop rapidly and are nearly transparent, researchers can watch how tumor cells behave in a living organism — whether they stay contained, spread, or die — within about one to two weeks. This is the fastest of the in-vivo functional testing methods, which matters when a patient needs to start treatment promptly.

For endometrial cancer, zebrafish avatars are particularly appealing for testing combinations that include both chemotherapy and immunotherapy-adjacent agents, since the zebrafish immune system shares enough features with the human immune system to capture some drug-immune interactions that pure cell culture cannot. Research use of zebrafish in gynecologic oncology is growing, and a small number of specialized laboratories in the United States and Europe now offer this as part of research programs, though it remains far from routine clinical use.

CAM assay (chorioallantoic membrane)

Turnaround: 1–2 weeks | Tissue needed: Small fragment | Least developed clinically

The CAM assay implants tumor tissue onto the highly vascular membrane of a fertilized chicken egg. The tumor recruits blood vessels and grows in a way that allows drug testing in a living system. It is fast and inexpensive, and it captures some aspects of how tumors interact with surrounding blood supply. For endometrial cancer specifically, this method is the least developed and least validated of the four approaches. It is used primarily as a research tool in laboratory settings and is not currently offered in clinical programs for treatment guidance. It is included here for completeness rather than as a practical option most patients will encounter.

Patient-derived xenografts (PDX)

Turnaround: 3–6 months | Tissue needed: Larger surgical specimen preferred | Highest biological fidelity

PDX models transplant actual patient tumor tissue directly into immune-suppressed mice, where it grows and maintains much of the original tumor's architecture and cellular diversity. For endometrial cancer, PDX establishment rates are generally moderate — roughly 30 to 50 percent depending on tumor subtype, with serous and copy-number-high tumors tending to engraft more readily than lower-grade endometrioid tumors. Hysterectomy specimens provide the most tissue and therefore the best engraftment conditions; Pipelle biopsy material is usually insufficient for reliable PDX establishment.

Once a PDX line is established, drugs are tested across multiple mice carrying the same patient's tumor, generating statistically meaningful data. PDX models are considered the gold standard for biological fidelity among functional testing approaches, but the 3-to-6-month timeline means they rarely inform a first-line treatment decision. They are more relevant for research programs studying recurrent or treatment-resistant disease, or for patients who have time to plan for a second-line treatment strategy. Several academic cancer centers maintain endometrial PDX biobanks for research.

How tissue is collected for functional testing

One of the most practical advantages endometrial cancer offers in this context is that the tissue collection is already built into the diagnostic workup. Your doctor will obtain tissue to confirm the diagnosis before any treatment begins. That same tissue — if handled correctly and sent to the right place — can be used to start growing organoids or prepare other functional models.

The most common collection methods are:

Pipelle biopsy: An office procedure lasting a few minutes in which a thin, flexible tube is passed through the cervix into the uterine cavity to aspirate a small sample. This is typically the first diagnostic step. For organoid work, a Pipelle sample can be sufficient if cell viability is maintained, but some laboratories prefer larger specimens.
Dilation and curettage (D&C): A short operating room or procedure suite procedure that collects a larger and more representative tissue sample. D&C specimens provide more material and are generally preferred when functional testing is planned alongside diagnosis.
Hysterectomy specimen: For patients proceeding to surgical staging, the hysterectomy provides abundant tumor tissue. This is the most favorable source for PDX establishment and provides ample material for organoids and biobanking.

The key logistical requirement is coordination before the procedure. Functional testing laboratories need fresh, living tissue — not formalin-fixed material used for routine pathology. That means the research team must be notified in advance so that a portion of the specimen is placed in specialized transport media and sent directly to the functional testing laboratory. Formalin-fixed tissue cannot be used for organoid culture or PDX, so retroactive participation is generally not possible once tissue has been processed by the pathology department in the standard way.

Timing and coordination matter: If you are interested in functional tumor testing, you must discuss it with your oncology team before your biopsy or surgery is scheduled — ideally at your first appointment. Once tissue has been fixed in formalin for standard pathology, it cannot be recovered for living tumor models. Early enrollment in a research program or early contact with a center that offers this work is essential. Last-minute requests are rarely accommodated.

Questions to ask your oncology team

Is my tumor a candidate for functional testing based on its stage, grade, or molecular subtype?
Is there an endometrial cancer organoid or PDX research program here, or can you refer me to one?
Can a portion of my biopsy or hysterectomy specimen be set aside for a living tumor model before it is fixed?
Are there open clinical trials at this center that incorporate functional tumor testing as part of the study design?
Would the results of a functional test actually change my treatment plan, or would they be for research only?
How long would it take to get results, and would that delay the start of my treatment?
Is there any cost to me for participating in a functional testing research program, or is it fully covered as part of the trial?
If I have recurrent disease, is functional testing more likely to be useful at that point than it is now?

Selecting a center

Most functional tumor testing for endometrial cancer currently takes place within research programs at academic cancer centers. The table below lists centers known to have gynecologic oncology programs with organoid, PDX, or functional testing research activity. This is not an exhaustive list, and programs change. Always verify current availability directly with the center.

Institution	Location	Known focus	How to inquire
Huntsman Cancer Institute (University of Utah)	Salt Lake City, UT	Gynecologic oncology program; Preclinical Cancer Models (PCM) Shared Resource supports organoid and PDX work; endometrial cancer research active	Ask your gynecologic oncologist at HCI about current research protocols; call HCI Clinical Trials Office at 801-585-0255
MD Anderson Cancer Center	Houston, TX	Established gynecologic oncology organoid and PDX program; endometrial PDX biobank; active translational research in uterine cancers	Ask at your first appointment about Uterine Cancer Program clinical trials; myMDAnderson patient portal for research enrollment questions
Memorial Sloan Kettering Cancer Center	New York, NY	Gynecologic oncology functional testing research; endometrial organoid models; POLE and dMMR subtype research	Contact MSK's Gynecology Service research coordinators; search open trials at mskcc.org/research/clinical-trials
Dana-Farber Cancer Institute	Boston, MA	Gynecologic oncology research including endometrial models; HER2-targeted therapy research for serous subtype; organoid culture programs	Ask your oncologist about research enrollment; Dana-Farber Clinical Trials Office at 617-632-3351
University of Pennsylvania (Penn Medicine)	Philadelphia, PA	Ovarian and endometrial cancer organoid models; translational research in gynecologic oncology; immunotherapy sensitivity testing	Penn Medicine Gynecologic Oncology; inquire at initial consultation about research protocols
Mayo Clinic	Rochester, MN (also Phoenix, AZ and Jacksonville, FL)	Gynecologic oncology translational research; endometrial cancer molecular subtyping and model development; PDX repository	Ask at your Mayo Clinic appointment about Gynecologic Oncology research participation; mayoclinic.org/research/clinical-trials

Limitations and honest caveats

Results do not always predict patient outcomes. Even when an organoid responds strongly to a drug in the lab, the patient's tumor may respond differently. Factors like immune cells, blood supply, drug distribution, and the patient's overall biology are not fully replicated in any current model. Published studies show correlation between organoid results and patient outcomes is real but imperfect.
Not all tumors successfully establish into models. Despite the favorable tissue access in endometrial cancer, roughly 15 to 30 percent of attempts to grow organoids will fail. Low-grade endometrioid tumors in particular can be slow-growing and difficult to maintain in culture. PDX engraftment rates are variable and depend heavily on tumor subtype.
The timeline may not fit your treatment schedule. Organoid results take 3 to 6 weeks at a minimum. For patients who need to start chemotherapy or immunotherapy within days of diagnosis, results will not be available in time to guide the first treatment decision. Functional testing is more likely to influence second-line decisions or clinical trial enrollment planning.
Hormonal therapy testing in organoids is promising but not validated. The ability to test progestins or aromatase inhibitors in endometrial organoids is scientifically interesting and potentially useful for fertility-sparing decisions, but this application has not yet been validated in prospective clinical studies with survival outcomes. Do not change a hormonal therapy plan based on organoid results alone without careful discussion with your oncologist.
Insurance coverage is not established. Functional tumor testing for treatment selection is not currently a covered benefit under Medicare or most private insurance plans for endometrial cancer. Participation is almost always through a funded research program where costs are absorbed by the study. Out-of-pocket programs exist but are expensive, and their clinical utility is not proven.
The field is moving fast — ask again if your situation changes. Programs that are not available today may be available in six months. If you are diagnosed with recurrent endometrial cancer, or if your disease stops responding to treatment, it is worth asking again whether functional testing research opportunities have opened up since your original diagnosis.

Key terms

Organoid: A small, three-dimensional cluster of living tumor cells grown in a lab gel that mimics the structure and behavior of the original tumor well enough to test how it responds to drugs.
dMMR / MSI-H: Deficient mismatch repair / microsatellite instability-high. A molecular feature of some endometrial tumors that makes them particularly responsive to immunotherapy drugs like pembrolizumab and dostarlimab. Tested routinely at diagnosis.
POLE mutation: A change in the POLE gene that causes tumors to accumulate large numbers of mutations. POLE-mutated endometrial cancers generally have an excellent prognosis and often respond well to immunotherapy, even at advanced stages.
PDX (patient-derived xenograft): A model in which actual patient tumor tissue is grown inside an immune-suppressed mouse. PDX models preserve much of the original tumor's biology and are used to test drug responses in a living organism.
Zebrafish avatar: A model in which patient tumor cells are injected into a zebrafish embryo for rapid drug testing, usually returning results within one to two weeks.
Copy-number high (serous-like): One of the four main molecular subtypes of endometrial cancer. These tumors often behave like high-grade serous ovarian cancer, tend to be more aggressive, and may express HER2 at levels that make them candidates for HER2-targeted therapy.
Functional testing: Any method that tests how living tumor cells actually respond to drugs — as opposed to genetic testing, which predicts response based on mutations. Functional testing observes drug effect directly rather than inferring it.
Drug sensitivity profile: The report generated from functional testing, showing which drugs (or drug combinations) reduced tumor cell growth in the lab and at what doses, and which had little or no effect.

This appendix is for educational purposes only and does not constitute medical advice. Functional tumor testing for endometrial cancer is investigational and is not a standard component of care. The institutions listed are examples only; Trouvera does not endorse any specific provider or program. Clinical trial availability, institutional programs, and insurance coverage change frequently — always verify current information directly with your care team. All treatment decisions should be made in consultation with a board-certified gynecologic oncologist based on established clinical guidelines.